Group-B type-II Coxsackie virus gene vaccine

A technology of coxsackie virus and gene vaccine, applied in gene therapy, antiviral agents, antibody medical ingredients, etc., can solve the problems of poor safety and poor immunogenicity

Inactive Publication Date: 2006-05-17
HARBIN MEDICAL UNIVERSITY
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The purpose of the present invention is to provide a kind of Coxsackie virus group B type 2 genetic vaccine for existing vaccines that have poor immunogenicity and poor safety, that is, a genetic vaccine for preventing and treating Coxsackie virus group B type 2 myocarditis, which is A pcDNA3-

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Group-B type-II Coxsackie virus gene vaccine
  • Group-B type-II Coxsackie virus gene vaccine
  • Group-B type-II Coxsackie virus gene vaccine

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0006] Specific embodiment one: The Coxsackievirus group B type 2 gene vaccine of this embodiment is a pcDNA3-CVB2VP1 eukaryotic expression plasmid composed of the eukaryotic expression system pcDNA3 and CVB2VP1 genes. For the gene sequences of CVB2VP1 and pcDNA3-CVB2VP1, see List of gene sequences.

specific Embodiment approach 2

[0007] Specific implementation mode two: This implementation mode introduces the CVB2 gene vaccine in detail.

[0008] 1. Materials:

[0009] (1) Viruses, cell lines, vectors and strains: CVB2 Yunnan isolate and HeLa cells were provided by Harbin Medical University. The cloning vector pMD18-T was purchased from TaKaRa Company (such as figure 1 shown), the eukaryotic expression vector pcDNA3 was purchased from Invitrogen (such as by figure 2 shown), the host strain is E.coliJM83, P-815 mouse mastocytoma cells (H-2 d Genotype) was provided by the State Key Laboratory of Biotechnology, Chinese Academy of Agricultural Sciences. The reference strains and GenBank accession numbers are shown in Table 1.

[0010] reference strain

GenBank accession number

Ohio-1

jo / Roma98

fr / Roma98

sp / Roma88

816 / 84

China-1

China-2

MD84-5914

HON84-6016

NC95-2135

FL92-1512

AF081312

AJ309267

AJ309266

AJ309252

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The group-B type-II coxsackie virus gene vaccine is one kind of vaccine for preventing coxsackie virus infection. The present invention aims at providing group-B type-II coxsackie virus gene vaccine as one kind of pcDNA3-CVB2VP1 eukaryotic expression plasmid comprising eukaryotic expression system pcDNA3 and CVB2VP1 gene. The gene vaccine of the present invention has the following advantages: direct DNA inoculation without complicated antigen preparing and purifying process, integrated and lasting immune response with antigen polypeptide submission similar to that in natural infection and no antigen epitope altering, common physical and chemical characteristics with capability of embedding several destination genes in the identical plasmid to form combined vaccine, simple preparation process with low cost and high safety and stability for easy storing and transportation.

Description

technical field [0001] The present invention relates to a vaccine for preventing Coxsackie virus infection. Background technique [0002] Vaccines traditionally used to prevent CVB (Coxsackie virus) infection include inactivated vaccines and live attenuated vaccines. During the inactivation process of inactivated vaccines, the antigenicity is weakened and important epitopes are lost, so that the body cannot produce sufficient protective immunity. Live attenuated vaccines often cause immunosuppression after inoculation. Insufficient attenuation can lead to clinical virus infection, and live virus vaccines may reverse mutations to produce pathogenic phenotypes, while over-attenuation will reduce the vaccine potency and weaken its efficacy. The ability to stimulate the body's immunity. New CVB vaccines include subunit vaccines and synthetic peptide vaccines. Subunit vaccines are safe, non-toxic, and have few side effects, but poor immunogenicity. In recent years, vaccines i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K39/00A61P31/12
Inventor 田野钟照华郭宏王言肖建敏孟繁超
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap